Acorah Software Products - Accounts Production 16.5.460 false true true 31 August 2024 1 September 2023 false 1 September 2024 31 August 2025 31 August 2025 12151270 Benjamin Leach Michael Leach Christopher Heys Daniel Rogerson Randal Pritchard iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12151270 2024-08-31 12151270 2025-08-31 12151270 2024-09-01 2025-08-31 12151270 frs-core:CurrentFinancialInstruments 2025-08-31 12151270 frs-core:ComputerEquipment 2025-08-31 12151270 frs-core:ComputerEquipment 2024-09-01 2025-08-31 12151270 frs-core:ComputerEquipment 2024-08-31 12151270 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-09-01 2025-08-31 12151270 frs-core:OtherResidualIntangibleAssets 2025-08-31 12151270 frs-core:OtherResidualIntangibleAssets 2024-09-01 2025-08-31 12151270 frs-core:OtherResidualIntangibleAssets 2024-08-31 12151270 frs-core:PlantMachinery 2025-08-31 12151270 frs-core:PlantMachinery 2024-09-01 2025-08-31 12151270 frs-core:PlantMachinery 2024-08-31 12151270 frs-core:WithinOneYear 2025-08-31 12151270 frs-core:SharePremium 2025-08-31 12151270 frs-core:ShareCapital 2025-08-31 12151270 frs-core:RetainedEarningsAccumulatedLosses 2025-08-31 12151270 frs-bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 12151270 frs-bus:FilletedAccounts 2024-09-01 2025-08-31 12151270 frs-bus:SmallEntities 2024-09-01 2025-08-31 12151270 frs-bus:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 12151270 frs-bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 12151270 frs-bus:OrdinaryShareClass1 2024-09-01 2025-08-31 12151270 frs-bus:OrdinaryShareClass1 2025-08-31 12151270 frs-bus:Director1 2024-09-01 2025-08-31 12151270 frs-bus:Director2 2024-09-01 2025-08-31 12151270 frs-bus:Director3 2024-09-01 2025-08-31 12151270 frs-bus:Director4 2024-09-01 2025-08-31 12151270 frs-bus:Director5 2024-09-01 2025-08-31 12151270 frs-countries:EnglandWales 2024-09-01 2025-08-31 12151270 2023-08-31 12151270 2024-08-31 12151270 2023-09-01 2024-08-31 12151270 frs-core:CurrentFinancialInstruments 2024-08-31 12151270 frs-core:WithinOneYear 2024-08-31 12151270 frs-core:SharePremium 2024-08-31 12151270 frs-core:ShareCapital 2024-08-31 12151270 frs-core:RetainedEarningsAccumulatedLosses 2024-08-31 12151270 frs-bus:OrdinaryShareClass1 2023-09-01 2024-08-31
Registered number: 12151270
Genomic Labs Ltd
Unaudited Financial Statements
For The Year Ended 31 August 2025
Genomic Labs Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—6

Page 1
Genomic Labs Ltd
Balance Sheet
As At 31 August 2025
Balance Sheet
Registered number: 12151270

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 1,016 |  | 2,540
Tangible Assets | 5 |  | 100,150 |  | 239,487
|  |  | 101,166 |  | 242,027
CURRENT ASSETS
Debtors | 6 | 1,347,408 |  | 833,930 |
Cash at bank and in hand |  | 1,001,054 |  | 867,637 |
|  | 2,348,462 |  | 1,701,567 |
Creditors: Amounts Falling Due Within One Year | 7 | (587,012 ) |  | (381,874 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 1,761,450 |  | 1,319,693
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 1,862,616 |  | 1,561,720
PROVISIONS FOR LIABILITIES
Deferred Taxation |  |  | (4,657 ) |  | (7,935 )
NET ASSETS |  |  | 1,857,959 |  | 1,553,785
CAPITAL AND RESERVES
Called up share capital | 8 |  | 14 |  | 14
Share premium account |  |  | 1,146,241 |  | 1,146,241
Profit and Loss Account |  |  | 711,704 |  | 407,530
SHAREHOLDERS' FUNDS |  |  | 1,857,959 |  | 1,553,785

Page 1
Page 2
Genomic Labs Ltd
Balance Sheet (continued)
As At 31 August 2025
For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Michael Leach Director
04/11/2025

The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Genomic Labs Ltd
Notes to the Financial Statements
For The Year Ended 31 August 2025
Notes to the Financial Statements
1. General Information
Genomic Labs Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12151270 . The registered office is Science Creates Old Market Lab 09, Midland Road, Bristol, BS2 0JZ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets relate to separately acquired trademaks. They are amortised to profit and loss account over the estimated economic life of five years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Lab Equipment | 3 years straight line
Computer and Office Equipment | 2-5 years straight line

2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.6. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
2.7. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
Page 3
Page 4
Genomic Labs Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 August 2025
2.8. Government Grant
Government grants are recognised in the profit and loss account in an appropriate manner that matches them with the expenditure towards which they are intended to contribute.
Grants for immediate financial support or to cover costs already incurred are recognised immediately in the profit and loss account. Grants towards general activities of the entity over a specific period are recognised in the profit and loss account over that period.
Grants towards fixed assets are recognised over the expected useful lives of the related assets and are treated as deferred income and released to the profit and loss account over the useful life of the asset concerned.
All grants in the profit and loss account are recognised when all conditions for receipt have been complied with.
2.9. Research and development costs
Research and development costs are written off to the profit and loss account in the year incurred.
2.10. Share based payments
The company has issued options over its unissued shares to certain employees. The cost of equity-settled transactions is measured by reference to the fair value of the equity instruments granted at the date at which they are granted and is recognised as an expense over the vesting period, which ends on the date on which the option holder becomes fully entitled to the award. Fair value is determined using the Black Scholes pricing model.
At each balance sheet date before vesting, the cumulative expense is calculated, representing the extent to which the vesting period has expired and management’s best estimate of the achievement or otherwise of non-market conditions and of the number of equity instruments that will ultimately vest. The movement in cumulative expense since the previous balance sheet date is recognised in the profit and loss account, with a corresponding entry in equity.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 24 (2024: 19)
24 19
4. Intangible Assets

| Trademark
--- | ---
| £
Cost
As at 1 September 2024 | 7,620
As at 31 August 2025 | 7,620
Amortisation
As at 1 September 2024 | 5,080
Provided during the period | 1,524
As at 31 August 2025 | 6,604
Net Book Value
As at 31 August 2025 | 1,016
As at 1 September 2024 | 2,540

Page 4
Page 5
Genomic Labs Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 August 2025
5. Tangible Assets

| Lab Equipment | Computer and Office Equipment | Total
--- | --- | --- | ---
| £ | £ | £
Cost
As at 1 September 2024 | 596,424 | 95,592 | 692,016
Additions | 7,873 | 15,138 | 23,011
As at 31 August 2025 | 604,297 | 110,730 | 715,027
Depreciation
As at 1 September 2024 | 430,678 | 21,851 | 452,529
Provided during the period | 114,726 | 47,622 | 162,348
As at 31 August 2025 | 545,404 | 69,473 | 614,877
Net Book Value
As at 31 August 2025 | 58,893 | 41,257 | 100,150
As at 1 September 2024 | 165,746 | 73,741 | 239,487

6. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Other debtors | 1,347,408 |  | 833,930

7. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 39,876 |  | 122,555
Other creditors | 497,921 |  | 215,722
Taxation and social security | 49,215 |  | 43,597
| 587,012 |  | 381,874

8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
Allotted, called up and fully paid | £ |  | £
1,356,508 Ordinary Shares of £ 0.00001 each | 14 |  | 14

9. Other Commitments
The company has operating leases relating to property. The total of future minimum lease payments under non-cancellable operating leases are as following:

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Not later than one year | 58,645 |  | 106,531
| 58,645 |  | 106,531

The amount of non-cancellable operating lease payments recognised as an expense during the year was
£209,157 (2024: £165,300).
Page 5
Page 6
Genomic Labs Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 August 2025
10. Share based payments
EMI share option scheme
Share options have been granted to certain employees under an EMI share option scheme. The options expire ten years after the grant date.
Included within administrative expenses is a share based payments expense of nil (2024: nil)
The movements in the number of share options during the year were as follows:
Outstanding at beginning of year: 47,843 (2024: 47,843)
Issued during the year: 13,500 (2024: nil)
Lapsed during the year: 18,534 (2024: nil)
Outstanding at end of year: 42,809 (2024: 47,843)
The weighted average exercise price of share options issued during the year was £3.06 per share (2024 - nil), and lapsed £0.64 (2024 - nil). The weighted average exercise price of all share options at the year end was £1.40 per share (2024 - £0.64).
Non-EMI share option scheme
Share options have been granted to certain members of management under an unapproved share option scheme. The options expire ten years after the grant date.
Included within administrative expenses is a share based payments expense of nil (2024: nil)
The movements in the number of share options during the year were as follows:
Outstanding at beginning of year: 19,833 (2024: 19,833)
Issued during the year: nil (2024: nil)
Outstanding at end of year: 19,833 (2024: 19,833)
The weighted average exercise price of share options issued during the year was nil (2024 - nil). The weighted average exercise price of all share options at the year end was £0.64 per share (2024 - £0.64).
Page 6